Alkermes plc. (ALKS) shareholders
ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30213% above fair value
$47.89+1.42 (+3.06%)
Close on Nov 11, 2026Market cap $8.03BP/E 126.0Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
178M of 168M shares
Institutional holders
424
90 new, 51 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 33 sales
Net sold $10.10M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 25,638,477 | 15.80% | 13G (passive) amendment | Mar 31, 2025 |
| Baker Bros. Advisors LP Joint filing with Baker Bros. Advisors (GP) LLC (6.10%), Julian C. Baker (6.10%) and 1 more | 10,012,267 | 6.10% | 13G (passive) | Dec 31, 2025 |
| Vanguard Portfolio Management | 9,647,056 | 5.80% | 13G (passive) | Mar 31, 2026 |
| Vanguard Capital Management | 8,676,888 | 5.21% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 8,540,351 | 5.20% | 13G (passive) | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALKS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 29,235,739 | 17.43% | $1.53B | +921,329 | 0.02% |
| Baker Bros. Advisors LP | 10,012,267 | 5.97% | $524.59M | – | 2.63% |
| Vanguard Portfolio Management LLC | 9,490,818 | 5.66% | $497.27M | −20,294 | 0.02% |
| State Street Corp | 9,160,575 | 5.46% | $479.97M | −304,711 | 0.01% |
| Vanguard Capital Management LLC | 7,515,025 | 4.48% | $393.75M | +87,628 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 6,737,328 | 4.02% | $353.00M | +2,072,752 | 0.04% |
| Renaissance Technologies LLC | 6,460,928 | 3.85% | $338.52M | +300,500 | 0.47% |
| Geode Capital Management, LLC | 4,477,876 | 2.67% | $234.66M | +295,609 | 0.01% |
| Dimensional Fund Advisors LP | 4,194,873 | 2.50% | $219.79M | −327,505 | 0.04% |
| Deep Track Capital, LP | 4,000,000 | 2.38% | $209.58M | +409,677 | 3.05% |
| American Century Companies Inc | 3,954,239 | 2.36% | $207.18M | −2,117,864 | 0.09% |
| Holocene Advisors, LP | 3,601,472 | 2.15% | $188.70M | +1,284,146 | 0.43% |
| Commodore Capital LP | 3,000,000 | 1.79% | $157.19M | −1,200,000 | 9.36% |
| Wellington Management Group Llp | 2,814,804 | 1.68% | $147.48M | −155,362 | 0.03% |
| Primecap Management Co/Ca/ | 2,528,680 | 1.51% | $132.49M | −11,310 | 0.08% |
| First Trust Advisors LP | 2,421,016 | 1.44% | $126.85M | −547,769 | 0.07% |
| Charles Schwab Investment Management Inc | 2,335,117 | 1.39% | $122.35M | +98,361 | 0.02% |
| Nuveen, LLC | 2,324,197 | 1.39% | $121.78M | −136,372 | 0.03% |
| Norges Bank | 2,156,814 | 1.29% | $113.01M | New | 0.01% |
| Bvf Inc/Il | 2,154,704 | 1.28% | $112.90M | +154,704 | 2.89% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 424 | 178M | 100.0% | 90 / 139 | 138 / 51 | 23M | 21M |
| Q1 2026 | 390 | 177M | 100.0% | 76 / 120 | 150 / 47 | 37M | 23M |
| Q4 2025 | 366 | 180M | 100.0% | 59 / 143 | 125 / 47 | 26M | 19M |
| Q3 2025 | 358 | 174M | 100.0% | 46 / 148 | 133 / 37 | 19M | 15M |
| Q2 2025 | 353 | 169M | 100.0% | 42 / 154 | 120 / 55 | 14M | 17M |
| Q1 2025 | 371 | 173M | 100.0% | 62 / 127 | 134 / 29 | 26M | 19M |
| Q4 2024 | 343 | 168M | 100.0% | 54 / 117 | 128 / 44 | 13M | 24M |
| Q3 2024 | 338 | 179M | 100.0% | 58 / 118 | 119 / 39 | 42M | 14M |
| Q2 2024 | 322 | 180M | 100.0% | 45 / 132 | 110 / 57 | 22M | 22M |
| Q1 2024 | 336 | 181M | 100.0% | 62 / 113 | 120 / 22 | 22M | 20M |
| Q4 2023 | 301 | 179M | 100.0% | 57 / 121 | 82 / 61 | 41M | 24M |
| Q3 2023 | 307 | 163M | 97.4% | 52 / 142 | 80 / 33 | 29M | 21M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Blair Curtis Jackson | President & CEO, Alkermes plc, Director | 241,308 | 0.14% | Aug 7, 2026 |
| Richard F. Pops | Director and CEO, Alkermes plc | 1,439,970 | 0.86% | Mar 4, 2026 |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 219,353 | 0.13% | Nov 3, 2026 |
| Joshua Reed | SVP, Chief Financial Officer | 5,095 | 0.00% | Oct 9, 2026 |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 74,389 | 0.04% | Sep 1, 2026 |
| Christian Todd Nichols | SVP, Chief Commercial Officer | 102,857 | 0.06% | Aug 17, 2026 |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 11,109 | 0.01% | May 29, 2026 |
| Iain Michael Brown | SVP, Chief Financial Officer | 148,196 | 0.09% | Feb 28, 2025 |
| Anne Clem Whitaker | Director | – | – | Oct 9, 2026 |
| nancy lynn snyderman MD | Director | 64,126 | 0.04% | Aug 3, 2026 |
| Christopher I. Wright | Director | 25,680 | 0.02% | Jun 12, 2026 |
| Frank Anders Wilson | Director | 35,751 | 0.02% | May 22, 2026 |
| Shane Cooke | Director | 106,679 | 0.06% | May 22, 2026 |
| Cato T. Laurencin | Director | 33,769 | 0.02% | May 22, 2026 |
| Brian P. McKeon | Director | 48,536 | 0.03% | May 22, 2026 |
| Richard Gaynor | Director | 37,226 | 0.02% | May 22, 2026 |
| Nancy Lurker | Director | 19,697 | 0.01% | May 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Nov 3, 2026 | Sale(10b5-1 plan) | −2,035 | $46.17 | $93.96K | 219,353 |
| Joshua Reed SVP, Chief Financial Officer | Oct 8, 2026 | Tax withholding | −4,069 | $40.11 | $163.21K | 5,095 |
| Joshua Reed SVP, Chief Financial Officer | Oct 8, 2026 | Option exercise | +9,164 | – | – | 9,164 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Oct 2, 2026 | Sale(10b5-1 plan) | −2,034 | $41.03 | $83.46K | 221,388 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Sep 3, 2026 | Sale(10b5-1 plan) | −2,034 | $48.01 | $97.65K | 223,422 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Sep 1, 2026 | Option exercise | +5,000 | $24.59 | $122.95K | 74,389 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −9,000 | $46.99 | $422.91K | 65,389 |
| Christian Todd Nichols SVP, Chief Commercial Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −6,912 | $49.19 | $340.00K | 102,857 |
| Christian Todd Nichols SVP, Chief Commercial Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −664 | $49.65 | $32.97K | 102,193 |
| nancy lynn snyderman MD Director | Aug 3, 2026 | Option exercise | +27,948 | $46.72 | $1.31M | 43,343 |
| nancy lynn snyderman MD Director | Aug 3, 2026 | Option exercise | +16,524 | $46.72 | $772.00K | 59,867 |
| nancy lynn snyderman MD Director | Aug 3, 2026 | Sale | −44,472 | $50.35 | $2.24M | 15,395 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Aug 3, 2026 | Sale(10b5-1 plan) | −2,034 | $48.58 | $98.81K | 225,456 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Aug 3, 2026 | Option exercise | +104 | $19.34 | $2.01K | 73,493 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Aug 3, 2026 | Option exercise | +4,896 | $24.59 | $120.39K | 78,389 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −9,000 | $48.58 | $437.22K | 69,389 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Jul 6, 2026 | Sale(10b5-1 plan) | −2,034 | $54.03 | $109.90K | 227,490 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Jul 1, 2026 | Option exercise | +5,000 | $19.34 | $96.70K | 82,389 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −8,300 | $51.46 | $427.12K | 74,089 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −700 | $52.13 | $36.49K | 73,389 |
| Christopher I. Wright Director | Jun 12, 2026 | Sale(10b5-1 plan) | −2,000 | $45.10 | $90.20K | 25,680 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Jun 4, 2026 | Sale(10b5-1 plan) | −2,034 | $43.05 | $87.56K | 229,524 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Jun 1, 2026 | Option exercise | +5,000 | $19.34 | $96.70K | 86,389 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −9,000 | $41.67 | $375.03K | 77,389 |
| Samuel Joseph Parisi VP, Finance (Interim PAO) | May 29, 2026 | Option exercise | +3,392 | $20.03 | $67.94K | 11,109 |
| Samuel Joseph Parisi VP, Finance (Interim PAO) | May 29, 2026 | Sale | −16,217 | $42.36 | $686.95K | 7,717 |
| Samuel Joseph Parisi VP, Finance (Interim PAO) | May 29, 2026 | Option exercise | +12,825 | $19.34 | $248.04K | 23,934 |
| nancy lynn snyderman MD Director | May 21, 2026 | Tax withholding | −1,475 | $36.95 | $54.50K | 15,395 |
| nancy lynn snyderman MD Director | May 21, 2026 | Option exercise | +6,142 | – | – | 16,870 |
| Shane Cooke Director | May 21, 2026 | Tax withholding | −3,207 | $36.95 | $118.50K | 106,679 |
| Shane Cooke Director | May 21, 2026 | Option exercise | +6,142 | – | – | 109,886 |
| Richard Gaynor Director | May 21, 2026 | Option exercise | +6,142 | – | – | 37,226 |
| Richard Gaynor Director | May 21, 2026 | Tax withholding | −1,475 | $36.95 | $54.50K | 35,751 |
| Frank Anders Wilson Director | May 21, 2026 | Tax withholding | −1,475 | $36.95 | $54.50K | 35,751 |
| Frank Anders Wilson Director | May 21, 2026 | Option exercise | +6,142 | – | – | 37,226 |
| Christopher I. Wright Director | May 21, 2026 | Tax withholding | −1,475 | $36.95 | $54.50K | 27,680 |
| Christopher I. Wright Director | May 21, 2026 | Option exercise | +6,142 | – | – | 29,155 |
| Cato T. Laurencin Director | May 21, 2026 | Tax withholding | −1,475 | $36.95 | $54.50K | 33,769 |
| Cato T. Laurencin Director | May 21, 2026 | Option exercise | +6,142 | – | – | 35,244 |
| Brian P. McKeon Director | May 21, 2026 | Tax withholding | −1,475 | $36.95 | $54.50K | 38,536 |
| Brian P. McKeon Director | May 21, 2026 | Option exercise | +6,142 | – | – | 40,011 |
| Nancy Lurker Director | May 21, 2026 | Option exercise | +6,142 | – | – | 19,697 |
| Nancy Lurker Director | May 21, 2026 | Tax withholding | −1,475 | $36.95 | $54.50K | 18,222 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | May 4, 2026 | Sale(10b5-1 plan) | −2,034 | $33.20 | $67.53K | 231,558 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | May 1, 2026 | Sale(10b5-1 plan) | −9,000 | $33.40 | $300.60K | 81,389 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | May 1, 2026 | Option exercise | +5,000 | $19.34 | $96.70K | 90,389 |
| Nancy Lurker Director | Apr 11, 2026 | Option exercise | +3,751 | – | – | 14,456 |
| Nancy Lurker Director | Apr 11, 2026 | Tax withholding | −901 | $33.36 | $30.06K | 13,555 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Apr 6, 2026 | Sale(10b5-1 plan) | −2,034 | $34.57 | $70.32K | 233,592 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Apr 1, 2026 | Option exercise | +5,000 | $19.34 | $96.70K | 94,389 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −9,000 | $35.51 | $319.59K | 85,389 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Mar 3, 2026 | Sale(10b5-1 plan) | −2,034 | $29.76 | $60.53K | 235,626 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Mar 2, 2026 | Option exercise | +5,000 | $19.34 | $96.70K | 98,389 |
| Craig C. Hopkinson EVP R&D, Chief Medical Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −9,000 | $29.72 | $267.48K | 89,389 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Mar 2, 2026 | Sale(10b5-1 plan) | −2,034 | $29.29 | $59.58K | 237,660 |
| Christian Todd Nichols SVP, Chief Commercial Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −6,000 | $30.00 | $180.00K | 109,769 |
| Samuel Joseph Parisi VP, Finance (Interim PAO) | Mar 2, 2026 | Sale(10b5-1 plan) | −6,890 | $29.29 | $201.81K | 7,717 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Feb 26, 2026 | Tax withholding | −3,049 | $30.73 | $93.70K | 239,694 |
| David Joseph Gaffin EVP, CLO, Alkermes, Inc. | Feb 26, 2026 | Option exercise | +6,866 | – | – | 242,743 |
| Blair Curtis Jackson EVP, Chief Operating Officer | Feb 26, 2026 | Tax withholding | −3,695 | $30.73 | $113.55K | 241,308 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
11.90%
20M shares short
Days to cover
11.3
At 2M shares a day
Change since last report
+3.1%
From 19M shares
Short volume, 20 days
60.0%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Alkermes's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,666 shares on Oct 6, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David Joseph Gaffin Officer | Nov 3, 2026 | 2,035 | $93.96K | Nov 3, 2026 | Vesting of restricted stock unit award |
| David Joseph Gaffin Officer | Oct 2, 2026 | 2,034 | $83.46K | Oct 2, 2026 | Vesting of restricted stock unit award |
| David Joseph Gaffin Officer | Sep 3, 2026 | 2,034 | $97.65K | Sep 3, 2026 | Vesting of restricted stock unit award |
| Craig C. Hopkinson Officer | Sep 1, 2026 | 9,000 | $422.87K | Sep 1, 2026 | Exercise of employee stock options |
| Christian Todd Nichols Officer | Aug 17, 2026 | 7,576 | $372.94K | Aug 17, 2026 | Vesting of restricted stock unit awards |
| Craig C. Hopkinson Officer | Aug 3, 2026 | 9,000 | $437.22K | Aug 3, 2026 | Exercise of employee stock options |
| David Joseph Gaffin Officer | Aug 3, 2026 | 2,034 | $98.81K | Aug 3, 2026 | Vesting of restricted stock unit award |
| nancy lynn snyderman MD Officer | Aug 3, 2026 | 44,472 | $2.24M | Aug 3, 2026 | Exercise of employee stock options |
| David Joseph Gaffin Officer | Jul 6, 2026 | 2,034 | $109.90K | Jul 6, 2026 | Vesting of restricted stock unit award |
| Craig C. Hopkinson Officer | Jul 1, 2026 | 9,000 | $463.62K | Jul 1, 2026 | Exercise of employee stock options |
| Christopher I. Wright Officer | Jun 12, 2026 | 2,000 | $90.20K | Jun 12, 2026 | Vesting of restricted stock unit awards |
| David Joseph Gaffin Officer | Jun 4, 2026 | 2,034 | $87.56K | Jun 4, 2026 | Vesting of restricted stock unit award |
| Craig C. Hopkinson Officer | Jun 1, 2026 | 9,000 | $375.04K | Jun 1, 2026 | Exercise of employee stock options |
| David Joseph Gaffin Officer | May 4, 2026 | 2,034 | $67.53K | May 4, 2026 | Vesting of restricted stock unit award |
| Craig C. Hopkinson Officer | May 1, 2026 | 9,000 | $300.56K | May 1, 2026 | Exercise of employee stock options |
See a number that looks wrong?